Register
Question 1
What technique is used to remove antibody bound to sensitized red blood cells?
Correct Answer:
Elution
Explanation:
Elution is the technique used to remove antibody bound to sensitized red blood cells. When red cells are coated with IgG in vivo, a direct antiglobulin test (DAT) can be positive. To identify which antibody is bound, the bound IgG is released from the cell surface into solution by an elution procedure (commonly acid treatment, which lowers the pH to disrupt antigen–antibody interactions). The eluate containing the released antibody is then tested against a panel of red cells to determine its specificity. This process helps distinguish the antibody causing the coating and is particularly useful for identifying alloantibodies when an autoantibody or mixed-field reactivity is present. Adsorption, precipitation, and neutralization involve different mechanisms or aims and do not detach bound antibody from the red cell surface.
Question 2
The red blood cells used for screening patients' serum for unexpected antibodies should be of what blood group?
Correct Answer:
O
Explanation:
Screening for unexpected antibodies uses red blood cells that won’t express A or B antigens, so any anti-A or anti-B antibodies in the patient’s serum won’t cause reactivity. Group O cells have no A or B antigens but still present a wide array of other clinically significant antigens (Rh, Kell, Duffy, Kidd, MNS, etc.), making them ideal for revealing antibodies against these non-ABO antigens. If cells expressing A or B were used, ABO antibodies in the serum could react with those antigens and complicate interpretation or create false-positive results, masking or confounding detection of antibodies to other antigens. Hence, the best choice is the cell group that lacks A and B antigens.
Question 3
Which population is particularly at risk for CMV infection?
Correct Answer:
Immunocompromised patients
Explanation:
CMV infection and its consequences are most likely to become clinically significant when the immune system is weakened. In healthy individuals, CMV is often acquired but kept in check, typically causing no or only mild symptoms. When immunity is compromised—such as in organ transplant patients on immunosuppressants, people with advanced HIV/AIDS, or those receiving chemotherapy—the virus can reactivate or spread more readily, leading to serious diseases like retinitis, pneumonitis, colitis, esophagitis, hepatitis, or encephalitis. This is why immunocompromised patients are the population particularly at risk for CMV infection and its complications, whereas healthy adults, teenagers, or athletes do not have the same elevated risk for severe CMV disease.
Question 4
Which viral agent causes the majority of transfusion-associated hepatitis?
Correct Answer:
Hepatitis C Virus
Explanation:
Transfusion-associated hepatitis is driven by viruses that can be transmitted through blood products. Hepatitis C virus is the primary agent here because it is efficiently transmitted via blood and, historically, accounted for most cases before donor screening and nucleic acid testing reduced the risk. Unlike Hepatitis A, which is mainly spread fecal-orally and not via blood, or Hepatitis D, which requires hepatitis B coinfection and is less common in transfusion cases, Hepatitis B is now largely controlled by vaccines and routine screening. The lack of a vaccine for hepatitis C and its tendency to cause silent, chronic infection also contributed to its prominence as the cause of transfusion-related hepatitis.
Question 5
As part of daily quality control, anti-B is tested against B cells. This procedure ensures what property of the antibody?
Correct Answer:
Antibody specificity
Explanation:
Antibody specificity. By testing anti-B against cells that carry the B antigen, you confirm that the reagent binds specifically to the B determinant and not to other cellular components. This ensures the antibody will react only with B antigen-bearing cells in routine testing, providing reliable, selective identification of the B antigen. This single QC step doesn’t measure how much antibody is present (titer), the antibody’s class (isotype), or the overall binding strength in multiple interactions (avidity); those require different tests or approaches.
Question 1
Exam overview

About this Exam

Prepare with the MT AAB Immunohematology Practice Test practice quiz. This question bank includes 10 questions covering blood, cells, antibody, screening, and group. Use it to review important concepts, identify knowledge gaps, and build confidence for the related exam, course, or assessment.

More details

Additional Information

MT AAB Immunohematology Practice Test

This practice set contains 10 questions from the matching question bank and focuses on blood, cells, antibody, screening, and group. Work through each question carefully, review the provided solutions, and revisit topics that need more study before your next attempt.

This is an independent study resource intended for practice and review; it is not an official examination or an endorsement by any organization named in the title.

Quiz information

Frequently Asked Questions

The complete question count is available after full access is unlocked.
No fixed duration is currently configured for this quiz.
Question explanations are included where they are available in the quiz content, helping you review the reasoning after answering.
Yes. You can retake the practice test again as you continue studying during your available access period.
After your access is confirmed, you can continue into the complete practice exam from this quiz flow.
Unless explicitly stated otherwise, this page provides independent practice material for study and exam preparation and is not the official examination itself.